Highbridge Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Highbridge Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-13,656	Closed	-$1.6M	–	1601
2017 Q3	$1.6M	Buy	+13,656	New	+$1.17M	0.02%	478
2016 Q4	–	Sell	-6,447	Closed	-$437K	–	1223
2016 Q3	$437K	Buy	+6,447	New	+$455K	0.01%	843
2016 Q2	–	Sell	-89,786	Closed	-$5.64M	–	1366
2016 Q1	$5.64M	Buy	+89,786	New	+$5.97M	0.09%	247
2015 Q3	–	Sell	-29,500	Closed	-$3.54M	–	1500
2015 Q2	$3.54M	Sell	29,500 -905	-3%	-$108K	0.04%	373
2015 Q1	$3.17M	Buy	+30,405	New	+$3.08M	0.04%	420
2014 Q2	–	Sell	-5,240	Closed	-$352K	–	1037
2014 Q1	$352K	Buy	5,240 +700	+15%	+$54.2K	﹤0.01%	795
2013 Q4	$292K	Buy	+4,540	New	+$271K	﹤0.01%	851
2013 Q3	–	Sell	-6,718	Closed	-$335K	–	1251
2013 Q2	$209K	Buy	+6,718	New	+$179K	﹤0.01%	1169

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

BRC

Blue Ridge Capital New York $215M AUM

Highbridge Capital Management's ALNY Position: Q4 2017 in Review

Highbridge Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2017, closing a stake of 13,656 shares — an estimated $1.6M sold.

Highbridge Capital Management first reported a position in ALNY in Q2 2013 and held it in 8 quarters. The position peaked at $5.64M in Q1 2016. 282 funds tracked by Wall St. Rank hold ALNY as of Q4 2017.

Highbridge Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
Highbridge Capital Management sold 13,656 Alnylam Pharmaceuticals shares in Q4 2017, an estimated $1.6M.
Highbridge Capital Management first reported a position in Alnylam Pharmaceuticals in Q2 2013 and held it in 8 quarters.
Highbridge Capital Management's Alnylam Pharmaceuticals position peaked at $5.64M in Q1 2016.
282 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2017.

Based on Highbridge Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.